Sun Pharmaceutical Industries Touched a fresh 52-wheek low of ₹ 1,548 during midday trading, declining 2.96 per cent to ₹ 1,579.20 as investor sentiment remained weak following us pressure Branded pharmaceuticals. The stock has Seen Heavy Selling Pressure with Over 52 Lakh Shares Traded, Generating Turnover of ₹ 827.93 Crore by 12.50 PM.

Cipla Showed related to better resilience, Falling a modest 0.87 per cent to ₹ 1,496.60, with trading volumes at 17.20 Lakh Shares Worth ₹ 256.73 Crore. The Stock Found Support Above ₹ 1,475 Levels, Significantly Above Its 52-White Low of ₹ 1,335.

Market Expert Ankit Patel from Arunasset Investment Services Offred a Measured Perspective on the tariff impact. “The 100 per cent tariff on branded and patented drugs is basically a protectionist shot at multinational firms shipping high-weight Medicines into the US,” Patel explained. He Emphahsized that Around 85-90 per cent of India’s Pharma Exports to the Us Are Generics, which remain outside the direct firing line.

Patel highlighted that bot sun pharma and cipla have existing manufacturing facilities in the us, providing them some protection under the examption class. “A less Indian Majors Like Sun, Cipla, Dr. Reddy’s and Lupin Alredy Run Facility in New Jersey, New York or Louisiana, which gives them some covers,” He noted.

The analyst concluded that the tariff pressure would primarily impact big pharma raather than Indian Generalic Manuftectrs, Thought Specialty Product SEGMENTS COCE FACE CHALD FACE CHALDEGES.

More like this

Published on September 26, 2025